Role of Metabolites in Nicotine Dependence (3) - 6
NCT00000289 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2017-01-12
Summary
The purpose of this study is to determine the effects of various doses of ondansetron transdermal nicotine replacement on tobacco withdrawal symptoms.
Conditions
- Tobacco Use Disorder
Interventions
- DRUG
-
Ondansetron
Sponsors & Collaborators
- collaborator OTHER
-
National Institute on Drug Abuse (NIDA)
lead NIH
Principal Investigators
-
Dorothy Hatsukami, Ph.D. · University of Minnesota
Study Design
- Purpose
- TREATMENT
- Masking
- DOUBLE
Eligibility
- Min Age
- 21 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-05-31
- Completion
- 2001-12-31
Countries
- United States
Study Locations
More Related Trials
-
The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence
NCT02590393 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Menthol in E-cigarettes on Smoking Behaviors
NCT04521647 ·Status: COMPLETED ·Phase: PHASE1
-
The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users
NCT02102100 ·Status: COMPLETED ·Phase: NA
-
Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge
NCT01075659 ·Status: COMPLETED ·Phase: PHASE2
-
Manipulating Tobacco Constituents in Female Menthol Smokers
NCT02048852 ·Status: COMPLETED ·Phase: NA
-
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
NCT02825459 ·Status: COMPLETED ·Phase: NA
-
Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users
NCT02792426 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Nicotine on Brain Reward Pathways
NCT02346539 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
NCT01228617 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
NCT00710034 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products
NCT01321931 ·Status: COMPLETED ·Phase: PHASE1
-
Medicinal Nicotine for Preventing Cue Induced Craving
NCT02347605 ·Status: COMPLETED ·Phase: NA
-
Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol
NCT03580525 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Smoking Cessation in Menthol Flavored Cigarette Smokers
NCT02342327 ·Status: COMPLETED ·Phase: NA
-
Effects of an Oral Nicotine Product in Smokeless Tobacco Users
NCT05280769 ·Status: COMPLETED ·Phase: NA
-
Effects of Chantix on Relapse Prevention for Smoking Cessation
NCT00948649 ·Status: COMPLETED ·Phase: PHASE4
-
Nicotine's Potential Abuse With Menthol
NCT04535362 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparative Acceptability of Tobacco and Menthol Flavored E-cigarettes
NCT04996940 ·Status: COMPLETED ·Phase: NA
-
Nicotine Replacement Therapy in Nicotine-dependent Arrestees
NCT02905734 ·Status: COMPLETED ·Phase: PHASE4
-
Human Laboratory Study Of Varenicline in Smokers
NCT00709696 ·Status: COMPLETED ·Phase: NA
-
Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation
NCT00419731 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® Gum
NCT01152736 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Cessation Preferences of Menthol Smoker
NCT02020005 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Electronic Cigarette Withdrawal Syndrome
NCT06066996 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Varenicline For Smokers In Recovery From Alcohol Dependence
NCT01092702 ·Status: COMPLETED ·Phase: PHASE2/PHASE3